+

MX2019012818A - Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos. - Google Patents

Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.

Info

Publication number
MX2019012818A
MX2019012818A MX2019012818A MX2019012818A MX2019012818A MX 2019012818 A MX2019012818 A MX 2019012818A MX 2019012818 A MX2019012818 A MX 2019012818A MX 2019012818 A MX2019012818 A MX 2019012818A MX 2019012818 A MX2019012818 A MX 2019012818A
Authority
MX
Mexico
Prior art keywords
memory
cognition
methods
cognitive disorders
treating
Prior art date
Application number
MX2019012818A
Other languages
English (en)
Inventor
Yuri Maricich
Original Assignee
Cavion Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cavion Inc filed Critical Cavion Inc
Publication of MX2019012818A publication Critical patent/MX2019012818A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80—Oxygen atoms
    • C07D239/82—Oxygen atoms with an aryl radical attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)

Abstract

La divulgación proporciona métodos para el tratamiento de enfermedades mediante la administración de compuestos farmacéuticos. En particular, la divulgación se refiere al tratamiento para mejorar la memoria o cognición, o para tratar un trastorno de la memoria o cognitivo, o para tratar síntomas cognitivos de una enfermedad o condición al administrar un antagonista de canales de calcio de tipo T.
MX2019012818A 2017-04-26 2018-04-26 Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos. MX2019012818A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762490377P 2017-04-26 2017-04-26
PCT/US2018/029616 WO2018200850A1 (en) 2017-04-26 2018-04-26 Methods for improving memory and cognition and for treating memory and cognitive disorders

Publications (1)

Publication Number Publication Date
MX2019012818A true MX2019012818A (es) 2020-07-14

Family

ID=63920133

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012818A MX2019012818A (es) 2017-04-26 2018-04-26 Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.

Country Status (11)

Country Link
US (1) US11324733B2 (es)
EP (1) EP3615521A4 (es)
JP (1) JP7321097B2 (es)
KR (1) KR102654466B1 (es)
CN (1) CN110770221B (es)
AU (1) AU2018260699B2 (es)
CA (1) CA3061720A1 (es)
IL (1) IL270180B (es)
MX (1) MX2019012818A (es)
SG (2) SG11201909960UA (es)
WO (1) WO2018200850A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2936400T3 (es) 2015-10-22 2023-03-16 Cavion Inc Métodos para tratar el síndrome Angelman
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2018152317A1 (en) 2017-02-15 2018-08-23 Cavion, Inc. Calcium channel inhibitors
AU2018260699B2 (en) 2017-04-26 2022-04-28 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders
CA3115235A1 (en) 2018-10-03 2020-04-09 Cavion, Inc. Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
JP7553453B2 (ja) 2019-03-01 2024-09-18 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
JPWO2022260016A1 (es) * 2021-06-07 2022-12-15
CN114129733A (zh) * 2021-12-08 2022-03-04 中国科学院深圳先进技术研究院 一种缓解焦虑及相关能量代谢紊乱的药物及其应用
CN116392490A (zh) * 2021-12-27 2023-07-07 中国科学院广州生物医药与健康研究院 氟桂利嗪的用途以及控制细胞内线粒体数量的方法
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
CN114601928B (zh) * 2022-04-02 2023-03-17 首都医科大学 一种钙超载介导神经元死亡的标志物及应用
WO2024152149A1 (zh) * 2023-01-16 2024-07-25 南京纽邦生物科技有限公司 花生四烯酸乙醇胺组合物及其应用
WO2025093735A2 (en) * 2023-11-01 2025-05-08 Drug Target Ip B.V. Agents for use in the treatment of tauopathies

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1319144C (en) 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
WO1993004047A1 (en) 1991-08-16 1993-03-04 Merck & Co., Inc. Quinazoline derivatives as inhibitors of hiv reverse transcriptase
NZ331217A (en) 1996-02-14 2000-02-28 Novartis Ag Sugar-modified gapped oligonucleotides for eliciting RNase H activity for strand cleavage in an opposing strand
AU2001235363A1 (en) 2000-02-25 2001-09-03 Novo-Nordisk A/S Mibefradil analogues and their use
AU2002303295B2 (en) 2001-04-06 2006-11-30 Univ New York Diagnosis and treatment of neural disease and injury using microvoltammetry
AU2003237616B2 (en) 2002-01-17 2007-07-05 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US20060003985A1 (en) * 2002-10-17 2006-01-05 Renger John J Enhancement of sleep with t-type calcium channel antagonists
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
EP1721607A1 (en) 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
US7166603B2 (en) 2003-07-23 2007-01-23 Bristol-Myers Squibb Co. Dihydropyrimidone inhibitors of calcium channel function
US7157461B2 (en) 2003-07-23 2007-01-02 Bristol-Myers Squibb Co. Substituted dihydropyrimidine inhibitors of calcium channel function
KR100610731B1 (ko) 2004-02-24 2006-08-09 한국과학기술연구원 Ｔ-형 칼슘 채널 차단제로서 유용한 ３,４-디히드로퀴나졸린유도체 및 그의 제조 방법
US7504431B2 (en) 2004-04-16 2009-03-17 Bristol-Myers Squibb Company Sulfonyl amide inhibitors of calcium channel function
EP1778245A4 (en) 2004-08-20 2010-03-03 Univ Virginia T-TYPE CALCIUM CHANNEL BLOCKER AND THE TREATMENT OF DISEASES
WO2006023883A2 (en) 2004-08-20 2006-03-02 University Of Virginia Patent Foundation T type calcium channel inhibitors
MX2007010965A (es) * 2005-03-09 2007-09-19 Merck & Co Inc Antagonistas de canales de calcio de tipo t de quinazolinona.
AU2006262101A1 (en) 2005-06-23 2007-01-04 Merck & Co., Inc. 3-fluoro-piperidine T-type calcium channel antagonists
EP1901746B1 (en) 2005-06-29 2013-02-20 Merck Sharp & Dohme Corp. 4-fluoro-piperidine t-type calcium channel antagonists
EP1906215A4 (en) 2005-07-14 2012-04-18 Teijin Chemicals Ltd FOAM SHEET AND LIQUID CRYSTAL DISPLAY
KR100654328B1 (ko) 2005-08-26 2006-12-08 한국과학기술연구원 피페라지닐알킬피라졸계 ｔ-타입 칼슘 채널 억제 화합물 및이의 제조방법
EP1968956A2 (en) 2005-12-22 2008-09-17 Icagen, Inc. Calcium channel antagonists
JP5269761B2 (ja) * 2006-04-12 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション ピリジルアミドｔ型カルシウムチャンネルアンタゴニスト
KR100743255B1 (ko) 2006-05-04 2007-07-27 한국과학기술연구원 Ｔ-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체
KR100749843B1 (ko) 2006-07-13 2007-08-21 한국과학기술연구원 Ｔ-타입 칼슘 채널에 억제 활성을 지닌 신규2,4-디옥소-퀴나졸린 유도체 및 이의 제조방법
KR100969686B1 (ko) 2006-08-07 2010-07-14 한국과학기술연구원 신규한 티아졸계 화합물 및 이를 함유하는 ｔ-형 칼슘 채널저해제
CA2663501A1 (en) 2006-09-15 2008-03-20 Schering Corporation Treating pain, diabetes, and disorders of lipid metabolism
JP2010503677A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション 脂質代謝の障害を治療するためのアゼチジノン誘導体
CN101534818A (zh) 2006-09-15 2009-09-16 先灵公司 用于治疗疼痛和脂类代谢疾病的氮杂环丁烷和氮杂环丁酮衍生物
JP2010503678A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション アゼチジノン誘導体およびその使用方法
JP2010503675A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション 疼痛、糖尿病および脂質代謝の障害の治療に有用なスピロ縮合アゼチジン誘導体
WO2008050200A1 (en) 2006-10-24 2008-05-02 Pfizer Products Inc. Oxadiazole compounds as calcium channel antagonists
US20080227823A1 (en) 2007-03-12 2008-09-18 Hassan Pajouhesh Amide derivatives as calcium channel blockers
WO2008112715A2 (en) * 2007-03-12 2008-09-18 Vm Discovery Inc. Novel agents of calcium ion channel modulators
WO2008117148A1 (en) 2007-03-23 2008-10-02 Pfizer Products Inc. Substituted oxadiazole analogs as calcium channel antagonists
WO2008138126A1 (en) 2007-05-09 2008-11-20 Neuromed Pharmaceuticals Ltd. Bicyclic pyrimidine derivatives as calcium channel blockers
KR100863239B1 (ko) 2007-05-23 2008-10-15 한국과학기술연구원 신규한 2-이미노-1,3-티아졸린계 화합물 및 이를 함유하는ｔ-형 칼슘 채널 저해제
AU2008275674A1 (en) 2007-07-10 2009-01-15 Merck & Co., Inc. Quinazolinone T-type calcium channel antagonists
KR101079459B1 (ko) 2007-09-14 2011-11-03 이화여자대학교 산학협력단 신규한 화합물, 이의 제조방법 및 이를 포함하는 통증억제용 조성물
JP2011500808A (ja) 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 複素環アミドｔ型カルシウムチャネルアンタゴニスト
RU2010120671A (ru) 2007-10-24 2011-11-27 Мерк Шарп Энд Домэ Корп. (Us) Гетероциклические фениламидные антагонисты кальциевых каналов т-типа
EP2211864A1 (en) 2007-10-24 2010-08-04 Merck Sharp & Dohme Corp. Pyrazinyl amide t-type calcium channel antagonists
WO2009056934A1 (en) 2007-10-31 2009-05-07 Pfizer Products Inc. 1,4-dihydronaphthyridine derivatives
KR100917037B1 (ko) * 2007-11-01 2009-09-10 한국과학기술연구원 피라졸릴카르복스아미도알킬피페라진 유도체 및 이의제조방법
US20090270413A1 (en) 2008-04-28 2009-10-29 Galemmo Jr Robert Di-t-butylphenyl piperazines as calcium channel blockers
CN102065858B (zh) * 2008-04-29 2014-07-02 法奈科斯公司 使用唑尼沙胺和阿坎酸治疗阿尔茨海默病和相关病症的组合组合物
US8377968B2 (en) 2008-06-02 2013-02-19 Zalicus Pharmaceuticals, Ltd. N-piperidinyl acetamide derivatives as calcium channel blockers
US20090298834A1 (en) 2008-06-02 2009-12-03 Hassan Pajouhesh 4-(aminomethyl)cyclohexanamine derivatives as calcium channel blockers
KR101014887B1 (ko) 2008-06-26 2011-02-15 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 이미다졸릴알킬카르보닐유도체 및 그의 제조방법
KR20100005476A (ko) 2008-07-07 2010-01-15 한국과학기술연구원 Ｔ-형 칼슘 채널에 활성을 지닌 신규 아이소인돌리논유도체 및 이의 제조방법
WO2010006103A1 (en) 2008-07-10 2010-01-14 Ore Pharmaceuticals Inc. Method for enhancing cognition or inhibiting cognitive decline
GB0813142D0 (en) * 2008-07-17 2008-08-27 Glaxo Group Ltd Novel compounds
KR101052620B1 (ko) 2008-08-28 2011-07-29 한국과학기술연구원 신규 페닐아세테이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 ｔ-형 칼슘 이온 채널의 활성에 의해 유발되는 질환의 예방 또는 치료용 조성물
KR101052065B1 (ko) 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
TW201028421A (en) 2009-01-15 2010-08-01 Abbott Lab Novel benzenesulfonamides as calcium channel blockers
CA2764499A1 (en) 2009-06-05 2010-12-09 Lloyd S. Gray Interlaced method for treating cancer or a precancerous condition
BR112012003179A2 (pt) 2009-08-12 2016-03-01 Carlos Alberto Barcelo Rojas sistema bio-eletrônico
JP5846372B2 (ja) 2010-01-29 2016-01-20 国立大学法人 岡山大学 Ｄｒａｖｅｔ症候群の発症可能性の判定方法およびその利用
US8575361B2 (en) 2010-03-02 2013-11-05 Concert Pharmaceuticals Inc. Tetrahydronaphthalene derivatives
WO2012032415A2 (en) 2010-09-08 2012-03-15 Pronova Biopharma Norge As Compositions comprising a fatty acid oil mixture comprising epa and dha in free acid form, a surfactant, and a statin
WO2012094612A1 (en) * 2011-01-07 2012-07-12 Zenyaku Kogyo Kabushikikaisha Method of treating essential tremor
BR112014028041A2 (pt) 2012-05-08 2017-06-27 Zafgen Inc tratamento de obesidade hipotalâmica com inibidores de metap2
CN105189775A (zh) 2013-01-10 2015-12-23 陶制药有限责任公司 用于治疗癌症的t-型钙通道抑制剂
WO2015149066A1 (en) 2014-03-28 2015-10-01 University Of Virginia Patent Foundation General anesthetics that are not neurotoxic
KR101679262B1 (ko) 2015-06-08 2016-11-24 한국과학기술연구원 4-이소프로필크로만-3-올 화합물
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
ES2936400T3 (es) 2015-10-22 2023-03-16 Cavion Inc Métodos para tratar el síndrome Angelman
CN105534977A (zh) * 2016-01-14 2016-05-04 山东大学 T型钙离子通道抑制剂nnc55-0396在制备抗神经退行性疾病药物中的应用
WO2018200844A1 (en) 2017-04-26 2018-11-01 Cavion, Inc. Methods for treating dravet syndrome
AU2018260699B2 (en) 2017-04-26 2022-04-28 Cavion, Inc. Methods for improving memory and cognition and for treating memory and cognitive disorders
GB2571978A (en) 2018-03-15 2019-09-18 Andre Fisahn Uses, compositions and methods
CA3115235A1 (en) 2018-10-03 2020-04-09 Cavion, Inc. Treating essential tremor using (r)-2-(4-isopropylphenyl)-n-(1-(5-(2,2,2-trifluoroethoxy)pyridin-2-yl)ethyl)acetamide
TWI870475B (zh) 2019-10-02 2025-01-21 美商卡凡恩公司 用於治療神經毒性之方法及材料

Also Published As

Publication number Publication date
KR102654466B1 (ko) 2024-04-08
EP3615521A1 (en) 2020-03-04
AU2018260699A1 (en) 2019-11-14
SG11201909960UA (en) 2019-11-28
KR20200003394A (ko) 2020-01-09
US11324733B2 (en) 2022-05-10
RU2019137952A (ru) 2021-05-26
CA3061720A1 (en) 2018-11-01
AU2018260699B2 (en) 2022-04-28
JP2020517701A (ja) 2020-06-18
EP3615521A4 (en) 2021-02-17
CN110770221A (zh) 2020-02-07
CN110770221B (zh) 2023-09-08
RU2019137952A3 (es) 2021-05-31
WO2018200850A1 (en) 2018-11-01
JP7321097B2 (ja) 2023-08-04
SG10202111885PA (en) 2021-12-30
IL270180B (en) 2022-06-01
US20200197377A1 (en) 2020-06-25

Similar Documents

Publication Publication Date Title
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
MX2018004947A (es) Metodos para el tratamiento de sindrome de angelman y de los trastornos relacionados.
PH12017500493A1 (en) Combination therapy
PH12017502142A1 (en) Tetrasubstituted aklene compounds and their use
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
MX376193B (es) Compuestos para tratar el cancer cerebral.
CL2017002242A1 (es) Método para tratar un tumor cerebral
MX363350B (es) COMPUESTOS DE SULFONA BICÍCLICA PARA LA INHIBICIÓN DE LA ACTIVIDAD RORgamma Y EL TRATAMIENTO DE ENFERMEDADES.
MX2018001435A (es) Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina.
BR112022002609A2 (pt) Métodos de tratamento de tumores estromais gastrointestinais
EA201991650A1 (ru) Способы лечения неврологических расстройств
PH12019500177A1 (en) Treatment and prevention of sleep disorders
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2020005545A (es) Compuestos para el tratamiento de trastornos neuromusculares.
EA201691567A1 (ru) Способы лечения легких травм головного мозга
EA201790352A1 (ru) Терапевтическое лечение на основе анаморелина
ZA202002936B (en) Phenoxy acids for the treatment of neuromuscular disorders
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2018009662A (es) Metodo y composicion farmaceutica para tratamiento de neurodegeneracion.
MX2023014484A (es) Uso de roluperidona para tratar sintomas y trastornos negativos, aumentar la neuroplasticidad y promover la neuroproteccion.
MX2019004804A (es) Tratamiento para el prurigo nodula.
PH12021552771A1 (en) Compounds for the treatment of neuromuscular disorders
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载